Author name: Sandra Cabo Verde

Personalized 3D Tumor models for Precision RadioTheranostics of Glioblastoma – TheraGlio-3D UTAustin Portugal exploratory project

Since the beginning of the 21st century, the multidisciplinary field of targeted radionuclide therapy (TRT) has been gaining increasing relevance.  However, most of targeted radionuclide therapy pre-clinical radiobiological studies have been performed in conventional in vitro cell culture systems, which fail to recapitulate some of the features of in vivo tumors. In this exploratory project […]

Personalized 3D Tumor models for Precision RadioTheranostics of Glioblastoma – TheraGlio-3D UTAustin Portugal exploratory project Read More »

C2TN participates in a new Research Project from the IAEA

Researchers from the Radiopharmaceutical Sciences Group of C2TN integrate a new Coordinated Research Project (CRP) from the IAEA, which had its first meeting in December in Vienna, Austria. This CRP aims to develop and carry out preclinical evaluation of Lu-177 radiopharmaceuticals targeting some of the major types of cancer. The consortium involves 16 Participating Countries

C2TN participates in a new Research Project from the IAEA Read More »

Development of Potential Lu-177 Radiopharmaceuticals: Design, Radiolabelling and Nonclinical Evaluation

Lutetium-177 (Lu-177) is currently the most important therapeutic radionuclide and it will continue to be a key role player in the nuclear medicine field, as its half-life of 6.65 days allows logistic of production and supply of radioisotope and finished product.  Currently there are over 70 radiopharmaceuticals for therapy in clinical trials and about 40%

Development of Potential Lu-177 Radiopharmaceuticals: Design, Radiolabelling and Nonclinical Evaluation Read More »

Scroll to Top